Neulasta is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever). Neulasta is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Therapeutic Indication
### Therapeutic indication Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Therapeutic Area (MeSH)
ATC Code
L03AA13
ATC Item
pegfilgrastim
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pegfilgrastim | N/A | Pegfilgrastim |
EMA Name
Neulasta
Medicine Name
Neulasta
Aliases
N/ANo risk management plan link.
